blank
logo-
Call: +66 64 505 5599

MENU

Call: +66 64 505 5599
logo-
Call: +66 64 108 5544
Call: +66 64 505 5599
knee-injection-ultrasound-guided

Who Should Perform Stem Cell Therapy for Knee OA

A patient walks into a regenerative medicine clinic. The space is clean and modern, the brochure uses words like “cutting-edge” and “scientifically advanced,” and the price is somewhere between $5,000 and $15,000 USD. They receive an injection and walk out the same day.

Nobody mentions what training the person holding the syringe actually has. Nobody explains where the cells came from, or what the protocol is if the joint reacts badly.

Stem cell therapy for knee osteoarthritis is one of the fastest-growing areas in regenerative medicine and one of the least regulated. The question patients should be asking is not simply whether stem cell therapy works. The question is who is qualified to administer it, and what happens when something goes wrong.

The Credentialing Problem Nobody Talks About

There is no universal standard for who can administer stem cell therapy. In many countries including several popular medical tourism destinations across Southeast Asia. The regulatory framework is either absent or inconsistently enforced.

“Regenerative medicine specialist” is a marketing title, not a medical credential. What matters is the underlying qualification: what the provider was trained to do, what anatomy they understand, and critically, what complications they are prepared to manage.

A physician specialising in orthopaedics or regenerative medicine treating knee OA has spent years understanding joint biomechanics, intra-articular anatomy, and infection risk. They can read an MRI, stage the disease accurately, and make a clinical judgment about whether a patient is actually a candidate for the procedure at all.

That assessment patient selection before any needle is picked up is where a significant portion of adverse outcomes are preventable. It is also the step most commonly skipped by commercial-first clinics.

Four Areas Where Provider Qualifications Change Outcomes

Not all stem cell procedures are equivalent. The gap between a well-executed procedure and a harmful one often comes down to four specific factors.

Cell Sourcing and Quality Verification

What is actually in the injection? In practice, this question is often unanswered. Some clinics sell platelet-rich plasma under the broader label of stem cell therapy. Others use allogeneic products from third-party labs with inconsistent quality controls. A qualified provider will verify cell viability, sourcing documentation, and storage handling and will explain each of these to the patient clearly. If a provider cannot answer where the cells came from and how viability was confirmed before your procedure, that is a clinical red flag.

Injection Precision

Placing a biological substance correctly inside the knee joint requires precision. Landmark-based injection estimating joint position by touch alone carries a meaningful rate of misplacement. Research on intra-articular knee injections shows that landmark-guided approaches miss the target in a notable percentage of cases. Image-guided injection using ultrasound to visualise needle placement significantly improves accuracy. Specialist providers trained in joint procedures are equipped to use imaging guidance where the anatomy or patient presentation warrants it.

Patient Selection Knowing When Not to Proceed

This is arguably the most important variable, and the one most frequently bypassed by high-volume commercial clinics. Stem cell therapy is not appropriate for all stages of knee osteoarthritis. Late-stage disease with severe joint space narrowing, bony deformity, or active infection risk requires a different treatment pathway entirely. A provider motivated primarily by volume has no structural incentive to disqualify a patient. A specialist accountable for outcomes does. Proper staging requires weight-bearing X-rays and ideally MRI to assess cartilage integrity and joint structure. Without that workup, any provider is operating without the information needed to make a safe clinical recommendation.

Complication Management

Complications from intra-articular injections are uncommon, but how a clinic responds when they occur matters as much as how the procedure is performed.

The difference between a specialist-led clinic and a commercial injection centre is not whether complications can happen. It is what happens next. At a non-specialist clinic, the standard response to any adverse event is an immediate referral out, to an emergency department or surgeon who has no knowledge of what was injected, what protocol was followed, or what the patient’s baseline looked like.

When the procedure is performed by a qualified surgeon from the relevant specialty orthopaedic, in the case of knee OA that physician can assess the complication directly, with full clinical context, and coordinate the appropriate escalation through established hospital referral pathways. The patient is not starting from zero with an unfamiliar team. That continuity of clinical knowledge in the first hours after a complication is where outcomes diverge.

What the Research Actually Shows

The current evidence base for stem cell therapy in knee OA is promising but still developing. A 2025 meta-analysis published in Frontiers in Cell and Developmental Biology, drawing on randomised controlled trials through October 2025, found that MSC therapy produced meaningful reductions in pain and improvements in joint function compared to control groups

A 2024 systematic review focused specifically on complications found that serious adverse events were rare overall, but were disproportionately associated with non-specialist settings linked to inadequate cell handling, absence of pre-procedural imaging workup, and injection without guidance.

The evidence points in a consistent direction: the safety profile of stem cell therapy for knee OA is shaped substantially by who administers it and under what clinical conditions not just by the biological properties of the cells themselves.

The Honest Answer

Specialist-led does not automatically guarantee better outcomes. There are rigorous non-surgical providers and there are specialists who have added regenerative injections without the appropriate infrastructure around them.

The distinction that matters is not the title on the door. It is the depth of pre-procedural assessment, the quality controls on the biological product, the precision of delivery, and the capacity to manage what comes after.

The single most clarifying question a patient can ask any provider before proceeding is this: “If this procedure causes a complication, who specifically handles that and how?”

The quality of that answer tells you nearly everything you need to know.

5 Questions to Ask Before Agreeing to Stem Cell Therapy for Your Knee

  • Where did the cells come from, and how was viability confirmed before my procedure?
  • Will imaging guidance be used during the injection?
  • What imaging has been reviewed to confirm I am an appropriate candidate?
  • What is the follow-up protocol, and how are outcomes tracked?
  • If I have a complication, who manages it and what does that process look like?

A provider who cannot answer all five clearly is not ready to treat you.

Medically reviewed by Dr. Naputt Virasathienpornkul, M.D.
Orthopedic Surgeon, Sports Medicine & Joint Conditions

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

www.ednawellness.com

References

Related Posts

error:Content is protected !!
blank